Cogent Biosciences signs commercial supply agreement with Hovione for bezuclastinib
Cogent Biosciences entered a Commercial Supply Agreement with Hovione to manufacture bezuclastinib spray-dried dispersion and tablets. Deal uses rolling quarterly forecasts with a binding near-term portion and minimum, declining purchase requirements.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.